CMV pneumonitis history and symptoms: Difference between revisions

Jump to navigation Jump to search
(Created page with "{{CMG}} {{CMV pneumonitis}} ==Overview== ==History and Symptoms== * CMV is usually asymptomatic in immunocompetent hosts. * Infected cells characteristically show ''large in...")
 
No edit summary
 
(One intermediate revision by one other user not shown)
Line 1: Line 1:
__NOTOC__
{{CMG}}
{{CMG}}
{{CMV pneumonitis}}
{{CMV pneumonitis}}
Line 10: Line 11:
* Involvement of most organ systems have been described, but the most common include pneumonitis, colitis, retinitis, hepatitis, pancreatitis, and meningoencephalitis.   
* Involvement of most organ systems have been described, but the most common include pneumonitis, colitis, retinitis, hepatitis, pancreatitis, and meningoencephalitis.   
*:* Patients will often present with a ''mononucleosis-like syndrome'' with fever/cough, myalgias, fatigue, headache, splenomegaly, and atypical lymphocytosis.  Pharyngitis and cervical lymphadenopathy are less common.
*:* Patients will often present with a ''mononucleosis-like syndrome'' with fever/cough, myalgias, fatigue, headache, splenomegaly, and atypical lymphocytosis.  Pharyngitis and cervical lymphadenopathy are less common.
* Symptoms may be present for 1-4 weeks before presentation; usually <2 weeks.
* The clinical presentation is variable depending on the severity of the illness, and ranges from a self-limited upper respiratory infection to progressive fatal pneumonia.  CMV inclusions may be found at autopsy in up to half of patients who die of HIV, of which half were probably not clinically significant.
* [[Fever]] (89-100%)
* [[Cough]] (76-94%) – often nonproductive
* [[Dyspnea]] (71-94%)
* Patients with CMV pneumonitis are likely to suffer from extrapulmonary CMV.
* Infected individuals are also at risk for coinfection with other pulmonary pathogens, such as PCP.
* Advanced AIDS is major risk factor for disease and mortality.
* CMV pneumonia may be seen following immunosuppression, such as with [[chemotherapy]].


==References==
==References==
{{Reflist|2}}
{{Reflist|2}}

Latest revision as of 18:33, 25 September 2012

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

CMV pneumonitis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating CMV pneumonitis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Criteria

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

CMV pneumonitis history and symptoms On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of CMV pneumonitis history and symptoms

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on CMV pneumonitis history and symptoms

CDC on CMV pneumonitis history and symptoms

CMV pneumonitis history and symptoms in the news

Blogs on CMV pneumonitis history and symptoms

Directions to Hospitals Treating CMV pneumonitis

Risk calculators and risk factors for CMV pneumonitis history and symptoms

Overview

History and Symptoms

  • CMV is usually asymptomatic in immunocompetent hosts.
  • Infected cells characteristically show large intranuclear inclusions with surrounding clearing, smaller cytoplasmic inclusions, and increased cell size.
  • CMV causes significant morbidity and mortality in transplant patients, and is the most common infection in lung transplant patients after bacterial pneumonia. CMV negative transplant patients who receive transplants from CMV negative donors usually are unaffected, but CMV positive or negative transplant patients who receive CMV positive or negative kidneys are at significant risk for CMV disease, and prophylaxis is now commonly given with CMV immune globulin or antivirals. Peak onset is 1-4 months post transplant.
  • Involvement of most organ systems have been described, but the most common include pneumonitis, colitis, retinitis, hepatitis, pancreatitis, and meningoencephalitis.
    • Patients will often present with a mononucleosis-like syndrome with fever/cough, myalgias, fatigue, headache, splenomegaly, and atypical lymphocytosis. Pharyngitis and cervical lymphadenopathy are less common.
  • Symptoms may be present for 1-4 weeks before presentation; usually <2 weeks.
  • The clinical presentation is variable depending on the severity of the illness, and ranges from a self-limited upper respiratory infection to progressive fatal pneumonia. CMV inclusions may be found at autopsy in up to half of patients who die of HIV, of which half were probably not clinically significant.
  • Fever (89-100%)
  • Cough (76-94%) – often nonproductive
  • Dyspnea (71-94%)
  • Patients with CMV pneumonitis are likely to suffer from extrapulmonary CMV.
  • Infected individuals are also at risk for coinfection with other pulmonary pathogens, such as PCP.
  • Advanced AIDS is major risk factor for disease and mortality.
  • CMV pneumonia may be seen following immunosuppression, such as with chemotherapy.

References